| Autor: |
Kilby, J. Michael, Hopkins, Sam, Venetta, Thomas M., DiMassimo, Betty, Cloud, Gretchen A., Lee, Jeannette Y., Alldredge, Leslie, Hunter, Eric, Lambert, Dennis, Bolognesi, Dani, Matthews, Thomas, Johnson, M. Ross, Nowak, Martin A., Shaw, George M., Saag, Michael S. |
| Předmět: |
|
| Zdroj: |
Nature Medicine; Nov1998, Vol. 4 Issue 11, p1302, 6p |
| Abstrakt: |
T-20, a synthetic peptide corresponding to a region of the transmembrane subunit of the HIV1 envelope protein, blocks cell fusion and viral entry at concentrations of less than 2 ng/ml in vitro. We administered intravenous T-20 (monotherapy) for 14 days to sixteen HIV-infected adults in four dose groups (3, 10, 30 and 100 mg twice daily). There were significant, dose-related declines in plasma HIV RNA in all subjects who received higher dose levels. All four subjects receiving 100 mg twice daily had a decline in plasma HIV RNA to less than 500 copies/ml, by bDNA assay. A sensitive RT-PCR assay (detection threshold 40 copies/ml) demonstrated that, although undetectable levels were not achieved in the 14-day dosing period, there was a 1.96 log[sub 10] median decline in plasma HIV RNA in these subjects. This study provides proof-ofconcept that viral entry can be successfully blocked in vivo. Short-term administration of T-20 seems safe and provides potent inhibition of HIV replication comparable to anti-retroviral regimens approved at present. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
